Imaging Biomarkers in Spastic Paraplegia Type 5 (NCT05174403) | Clinical Trial Compass
CompletedNot Applicable
Imaging Biomarkers in Spastic Paraplegia Type 5
France10 participantsStarted 2022-01-28
Plain-language summary
This is a research study aiming to identify imaging biomarkers in patients diagnosed with spastic paraplegia type 5 (SPG5)
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
* At least 18 years of age
* Signature of the informed consent
* Covered by social security
* SPG5 patients identified with two mutations in the CYP7B1 gene
Exclusion criteria
* Contra-indications to MRI (claustrophobia, metallic or material implants)
* Additional psychiatric or neurological conditions / additional major comorbidities
* History of severe head injury
* Participation in another trial (except observational trial)
* Pregnancy and breastfeeding
* Inability to understand information about the protocol
* Persons under AME
* Persons deprived of their liberty by judicial or administrative decision
* Adult subject under legal protection or unable to consent
* Unwillingness to be informed in case of abnormal MRI
What they're measuring
1
Changes in the cross-sectional area in the spine of SPG5 patients